Twist Bioscience (NASDAQ:TWST) Research Coverage Started at BWS Financial

BWS Financial initiated coverage on shares of Twist Bioscience (NASDAQ:TWST) in a research report released on Wednesday morning, Marketbeat.com reports. The brokerage issued a sell rating and a $45.00 target price on the stock.

A number of other research firms have also commented on TWST. Evercore lowered Twist Bioscience from an “outperform” rating to an “in-line” rating and set a $102.00 price objective on the stock. in a research note on Monday, July 6th. Robert W. Baird increased their target price on Twist Bioscience from $113.00 to $115.00 and gave the stock an “outperform” rating in a report on Tuesday, August 4th. UBS Group assumed coverage on Twist Bioscience in a research note on Wednesday. They issued a “neutral” rating and a $144.00 target price for the company. Piper Sandler lifted their price target on Twist Bioscience from $85.00 to $115.00 and gave the company an “overweight” rating in a report on Wednesday, August 5th. Finally, Guggenheim reiterated a “buy” rating on shares of Twist Bioscience in a research report on Monday, August 24th. Eight analysts have rated the stock with a Buy rating, two have issued a Hold rating and two have given a Sell rating to the stock. According to data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and a consensus target price of $98.45.

Twist Bioscience Stock Performance

NASDAQ:TWST opened at $127.22 on Wednesday. Twist Bioscience has a 1 year low of $23.30 and a 1 year high of $155.44. The firm has a 50 day moving average of $113.51 and a 200-day moving average of $79.33. The company has a current ratio of 2.67, a quick ratio of 2.38 and a debt-to-equity ratio of 0.03. The stock has a market capitalization of $7.98 billion, a P/E ratio of -57.31 and a beta of 2.22.

Twist Bioscience (NASDAQ:TWST) last announced its earnings results on Monday, August 3rd. The company reported ($0.56) EPS for the quarter, missing the consensus estimate of ($0.51) by ($0.05). The business had revenue of $118.38 million during the quarter, compared to analyst estimates of $114.55 million. Twist Bioscience had a negative return on equity of 28.64% and a negative net margin of 31.66%.The firm’s revenue was up 23.2% compared to the same quarter last year. During the same period in the previous year, the firm earned $0.33 earnings per share. As a group, sell-side analysts anticipate that Twist Bioscience will post -2.12 EPS for the current fiscal year.

Insider Activity at Twist Bioscience

In other Twist Bioscience news, SVP Paula Green sold 291 shares of the company’s stock in a transaction on Monday, June 22nd. The stock was sold at an average price of $87.32, for a total transaction of $25,410.12. Following the transaction, the senior vice president owned 120,414 shares of the company’s stock, valued at approximately $10,514,550.48. This represents a 0.24% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, insider Dennis Cho sold 14,205 shares of the stock in a transaction on Wednesday, June 24th. The shares were sold at an average price of $89.75, for a total value of $1,274,898.75. Following the completion of the transaction, the insider owned 105,141 shares in the company, valued at $9,436,404.75. The trade was a 11.90% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last 90 days, insiders have sold 193,109 shares of company stock worth $24,049,024. Company insiders own 3.08% of the company’s stock.

Hedge Funds Weigh In On Twist Bioscience

Hedge funds have recently added to or reduced their stakes in the company. Royal Bank of Canada increased its position in Twist Bioscience by 11.8% in the first quarter. Royal Bank of Canada now owns 40,373 shares of the company’s stock worth $1,585,000 after purchasing an additional 4,254 shares during the period. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. lifted its position in Twist Bioscience by 4.7% during the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 70,310 shares of the company’s stock valued at $2,765,000 after purchasing an additional 3,181 shares during the period. Goldman Sachs Group Inc. boosted its stake in shares of Twist Bioscience by 4.2% in the 1st quarter. Goldman Sachs Group Inc. now owns 932,978 shares of the company’s stock valued at $36,629,000 after purchasing an additional 37,577 shares during the last quarter. Intech Investment Management LLC boosted its stake in shares of Twist Bioscience by 18.9% in the 1st quarter. Intech Investment Management LLC now owns 28,917 shares of the company’s stock valued at $1,135,000 after purchasing an additional 4,591 shares during the last quarter. Finally, Norges Bank acquired a new stake in shares of Twist Bioscience during the 2nd quarter worth approximately $737,000.

Twist Bioscience Company Profile

Twist Bioscience Corporation is a biotechnology company that develops and manufactures synthetic DNA using a proprietary silicon-based platform. The company serves researchers and organizations in biotechnology, pharmaceutical development, agriculture, industrial chemicals and academic research.

Its products include synthetic genes, gene fragments, oligonucleotides and DNA libraries used in research, drug discovery, diagnostics development and other applications. Twist also provides next-generation sequencing tools and products, including target-enrichment and sample-preparation solutions, as well as synthetic biology services that support the design and testing of biological systems.

Twist was founded in 2013 and is headquartered in South San Francisco, California.